Sabrina Serani

Researchers explore DNA methylation patterns for early ovarian cancer detection, aiming to improve survival rates through innovative blood tests.

Research advances in blood cancer treatment enhance donor matching and reduce graft-vs-host disease, improving access to life-saving transplants for diverse patients.

A new triple therapy shows promising results for treating BRAF V600E-mutant metastatic colorectal cancer, significantly improving patient outcomes.

Zymeworks discontinues ZW171 clinical development after phase 1 trial reveals unfavorable benefit-risk profile, shifting focus to other promising candidates.

Researchers explore TAF1's role in leukemia, revealing potential targeted therapies that could transform treatment approaches for acute myeloid leukemia.

New clinical trial results reveal annamycin's promise in treating relapsed AML, showing improved survival rates and a favorable safety profile.

The FDA approves a long-acting injectable for advanced prostate cancer, offering a convenient quarterly dosing option and improved patient care.

Sonrotoclax shows promise as a new treatment for relapsed/refractory mantle cell lymphoma, achieving significant response rates in heavily pretreated patients.

Abemaciclib significantly enhances survival rates in high-risk early breast cancer, establishing its role as a standard treatment alongside endocrine therapy.

A groundbreaking study reveals how the Decipher Prostate Genomic Classifier personalizes chemotherapy decisions for metastatic prostate cancer patients, enhancing treatment outcomes.

VGT-1849B receives FDA orphan drug designation, promising a targeted treatment for polycythemia vera with improved safety and efficacy.

TT125-802, a promising bromodomain inhibitor, gains FDA fast track status for treating advanced non-small cell lung cancer, addressing critical patient needs.

FDA reviews gedatolisib for advanced breast cancer, showing significant progression-free survival improvements in pivotal VIKTORIA-1 trial.

The European Commission approves tislelizumab for neoadjuvant treatment of resectable NSCLC, enhancing survival rates and offering new hope for patients.

A pivotal trial evaluates patritumab deruxtecan for advanced HR-positive, HER2-negative breast cancer, offering hope for patients after standard therapies.

A novel assay identifies low-risk patients with high-risk ER+/HER2– early breast cancer, potentially sparing them from unnecessary treatment escalation.

New studies reveal how the DecisionDx-SCC test enhances treatment decisions for high-risk cutaneous squamous cell carcinoma, improving patient outcomes.

In a pilot study, a novel regimen showed 100% disease control in 5 patients with recurrent GBM, with 2 achieving near complete response.

FDA breakthrough therapy designation granted for rinatabart sesutecan in endometrial cancer, based on encouraging data from a phase 1/2 trial.

Final data from the VERSATILE-002 trial for HPV16-positive HNSCC shows a median overall survival of 39.3 months with PDS0101 plus pembrolizumab.

The FDA has granted breakthrough device designation to the Haystack MRD test, a circulating tumor DNA (ctDNA) test, for use in patients with stage II colorectal cancer following surgery.

Innovent's bispecific antibody, IBI363, enters a global phase 3 trial for IO-resistant lung cancer, the first of its kind, offering new hope for this patient group.

Dordaviprone received accelerated FDA approval for H3 K27M-mutant diffuse midline glioma, an aggressive brain tumor, making it the first approved systemic therapy for this rare disease.

A trade agreement between the US and EU sets a 15% tariff on most European pharma imports, impacting oncology drug supplies and potentially costing the industry billions.

A new study suggests the MAGIC Composite Response metric, which combines clinical and biomarker data, improves prediction of outcomes for acute GVHD.

Research reveals innovative methods for detecting minimal residual disease in ovarian cancer, enhancing prognosis and paving the way for targeted therapies.

Alpha1H shows promising results in treating non-muscle-invasive bladder cancer, demonstrating significant tumor response and a strong safety profile in clinical trials.

The FDA approves Agilent's MMR IHC Panel, enhancing personalized colorectal cancer treatment by identifying patients for targeted immunotherapy options.

New combination therapy shows promising results for advanced non-small cell lung cancer, offering hope for patients with limited treatment options.

New research reveals that GLP-1 receptor agonists significantly lower mortality risk in older cancer patients with type 2 diabetes compared to other treatments.